Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1780 - Number of deliveries as a prognostic factor in different breast cancer subtypes

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Anniina Jääskeläinen

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

A. Jääskeläinen1, N. Roininen1, A. Jukkola2, P. Karihtala1

Author affiliations

  • 1 Department Of Oncology And Radiotherapy, Medical Research Center, Oulu University Hospital and University of Oulu, 90229 - Oulu University Hospital/FI
  • 2 Department Of Oncology And Radiotherapy, Tampere University Hospital and University of Tampere, 33521 - Tampere/FI
More

Resources

Abstract 1780

Background

Some registry-based and population-based studies have suggested that high parity could be an adverse prognostic factor in luminal breast cancer, although the definition of breast cancer subtypes has been varied and prospective studies are lacking.

Methods

We report long-term follow-up (median 8.5 years) from prospectively collected single-institution material of early breast cancers. The patients (n = 612) were treated with modern treatment modalities in a Finnish university hospital clinic and clinicopathological surrogates of intrinsic subtypes were updated to match with the ESMO 2015 Early Breast Cancer Clinical Practice Guidelines. Long-term outcomes were recorded and special emphasis was given to exact reproductive factor anamnesis as a potential prognostic factor.

Results

Ten-year breast cancer-specific survival (BCSS) in this real-life prospective population was 91.4% in the whole cohort. The longest ten-year BCSS was observed in luminal A-like cancers (97.6%) and the worst in luminal B-like (HER2-positive) subgroup (80.6%). Having five or more deliveries associated with dismal BCSS (univariate p = 0.0015). When subtypes were assessed separately in multivariate analysis, this association remained significant only in luminal B-like (HER2-negative) cancers (HR 2.64; 95% CI 1.05-6.65; p = 0.04) when tumor size and nodal status were also included to the analysis. Having 5 or more deliveries also associated with node positivity in the whole cohort (p = 0.0016), but not with different subtypes.

Conclusions

This is the first prospectively collected study with the modern definition of breast cancer subtypes and contemporary treatments to assess parity as a breast cancer prognostic factor. Our results suggest that high parity is an adverse prognostic factor, but only in luminal B-like (HER2-negative) subtype. The biological effects of parity seem extend to later breast cancer and its metastasis in estrogen dependent, rapidly proliferating breast cancers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings